Draft:John Simard
John Simard | |
|---|---|
| Born | John Simard 1962 |
| Alma mater | University of Saskatchewan University of Toronto |
| Occupation | Businessperson |
John Simard (born 1962) is a Canadian-born biotechnology entrepreneur and the founder and CEO of XBiotech.[1][2]
Early life and education
[edit]John Simard was born in 1962 in Vancouver, British Columbia, Canada.[1] He earned a biochemistry degree from the University of Saskatchewan in 1992, then pursued immunology at the University of Toronto's Department of Medical Biophysics.[3][4]
In 1994, Simard left his graduate program to work with Tak W. Mak at the Amgen Research Institute.[4] Later, he co-authored a textbook on immunology with Mak.[4] He also co-authored a manuscript with Nobel Laureate Rolf Zinkernagel, focusing on the biology of cytotoxic T lymphocytes (CTL).[4]
Career
[edit]Simard began his career in biotechnology by establishing CTL Immunotherapies in 1997, which focused on vaccine development.[1][5] Later, he also founded AlleCure Corp. in Valencia, California, which developed allergy treatments and immune modulating therapies.[6][5] His first two companies were eventually merged with MannKind Corporation.[1][7][8]
In 2005, Simard founded XBiotech, which specializes in the research and development of human-derived antibody therapeutics for cancer, inflammatory and infectious diseases.[1][3]
Research
[edit]Simard has developed therapies targeting interleukin-1a, including a neutralizing antibody that was sold for a total of $1.35 billion in cash and milestone payments.[9][4] He holds over 300 issued and pending patents in areas such as cancer antigen identification, immunotherapies for cancer and infectious diseases, and techniques for identifying and cloning human antibodies.[4]
References
[edit]- ^ a b c d e https://www.bizjournals.com/austin/print-edition/2014/10/17/meet-john-simard-ceo-of-xbiotech.html
- ^ https://www.bizjournals.com/austin/news/2020/06/11/austins-top-paid-ceos.html
- ^ a b "John Simard, Xbiotech USA Inc: Profile and Biography". Bloomberg.com.
- ^ a b c d e f "John Simard". XBiotech.
- ^ a b Rockwell, Lilly. "How Austin's XBiotech aims to revolutionize drug discovery". Austin American-Statesman.
- ^ Institute, ERI Economic Research. "John Simard Salary Infomation 2022". ERI Economic Research Institute.
- ^ https://labusinessjournal.com/news/biotech-mann-slates-biotech-ipo-by-year-end/
- ^ https://www.bizjournals.com/austin/print-edition/2011/01/28/xbiotech-has-huge-plans.html
- ^ https://www.bizjournals.com/austin/news/2020/02/10/1-35b-deal-offers-vindication-runway-for-austin.html